Payment overview · 2025
General Payments
$1,616.38
87 reported records · 29 companies
Healthcare provider profile · identity verified
Daniel Lee Holt, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WASHINGTON, PA · NPI 1922003375
Verified facts
What the public records show
CMS Open Payments records show Daniel Lee Holt, M.D. received $1,616.38 in general payments during 2025 across 87 reported records.
Novo Nordisk Inc accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 51 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Glassia, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GLASSIA as an associated drug or biological on 7881 records involving 3215 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Glassia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $267.24 | 16.5% | 20 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $185.62 | 11.5% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $156.04 | 9.7% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $142.34 | 8.8% | 9 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $92.85 | 5.7% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $76.40 | 4.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $67.86 | 4.2% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.29 | 3.2% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $50.44 | 3.1% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $42.39 | 2.6% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $41.49 | 2.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $41.14 | 2.5% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $39.53 | 2.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.27 | 2.3% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $33.44 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.82 | 2.0% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $31.25 | 1.9% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $28.07 | 1.7% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $24.01 | 1.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.99 | 1.5% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $20.23 | 1.2% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $18.97 | 1.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.03 | 1.1% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $17.44 | 1.1% | 1 | 2025 |
| Vifor Pharma, Inc. | Unresolved — no canonical attribution shown | $17.33 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.00 | 1.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.97 | 1.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.44 | 0.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.49 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,616.38 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $149.59 | 9 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $119.47 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $119.47 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $119.47 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $86.29 | 5 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $76.40 | 3 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $71.64 | 4 | 2025 |
Source payment records
|
|||||
| GLASSIA Normalized: glassia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $71.45 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $67.86 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $57.43 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.51 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $53.51 | 4 | 2025 |
Source payment records
|
|||||
| PEDIARIX Normalized: pediarix |
Biological | GlaxoSmithKline, LLC. | $53.28 | 3 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $53.28 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $50.44 | 3 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $42.39 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $41.49 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $41.14 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $41.14 | 3 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $39.53 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $39.53 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $39.53 | 1 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $36.03 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $33.44 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $31.63 | 2 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $31.25 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $28.07 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $20.23 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.35 | 1 | 2025 |
Source payment records
|
|||||
| Veltassa Normalized: veltassa |
Drug | Vifor Pharma, Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.61 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $13.49 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| GLASSIA glassia |
2025 | Glassia | 2024 | 100 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
74 | 11 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
88 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 20 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GLASSIA open payments reported associated product |
CMS Open Payments — General Payments 7881 supporting records · 3215 recipient NPIs · example record 1223616286 |
Glassia · 2024 Exact normalized brand match · 1 Part D row |
100 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 455 | 101 |
| Omeprazole | Omeprazole | 350 | 66 |
| Simvastatin | Simvastatin | 341 | 89 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 61 |
| Metformin Hcl | Metformin Hcl | 298 | 65 |
| Gabapentin | Gabapentin | 297 | 53 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 224 | 49 |
| Lisinopril | Lisinopril | 220 | 60 |
| Losartan Potassium | Losartan Potassium | 203 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 164 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 35 |
| Tramadol Hcl | Tramadol Hcl | 127 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 125 | 32 |
| Lorazepam | Lorazepam | 108 | 26 |
| Eliquis | Apixaban | 106 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 23 |
| Sertraline Hcl | Sertraline Hcl | 103 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 102 | 25 |
| Famotidine | Famotidine | 101 | 25 |
| Glassia | Alpha-1-Proteinase Inhibitor | 100 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 100 | 17 |
| Carvedilol | Carvedilol | 95 | 23 |
| Celecoxib | Celecoxib | 93 | 15 |
| Ozempic | Semaglutide | 90 | 18 |
| Trulicity | Dulaglutide | 88 | 16 |
| Furosemide | Furosemide | 76 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 74 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 14 |
| Atenolol | Atenolol | 69 | 20 |
| Alendronate Sodium | Alendronate Sodium | 68 | 11 |
| Pregabalin | Pregabalin | 68 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 62 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | suppressed |
| Allopurinol | Allopurinol | 57 | 14 |
| Ibuprofen | Ibuprofen | 55 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 14 |
| Potassium Chloride | Potassium Chloride | 54 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 13 |
| Glipizide Er | Glipizide | 50 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 45 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Amoxicillin | Amoxicillin | 39 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 26 |
| Aralast Np | Alpha-1-Proteinase Inhibitor | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 19 |
| Jardiance | Empagliflozin | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Prednisone | Prednisone | 31 | 13 |
| Alprazolam | Alprazolam | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Glipizide | Glipizide | 29 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Nifedipine Er | Nifedipine | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 13 |
| Finasteride | Finasteride | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Nystatin | Nystatin | 21 | 11 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 17 |
| Baclofen | Baclofen | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Etodolac | Etodolac | 20 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Rufinamide | Rufinamide | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Perphenazine | Perphenazine | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,616.38 · 87 records | Novo Nordisk Inc | ABRYSVO, AREXVY, BEXSERO, BEYFORTUS, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ENTRESTO, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, GARDASIL 9, GLASSIA, GVOKE HYPOPEN, Hizentra, INSPIRE, JARDIANCE, JOURNAVX, LEQVIO, MOUNJARO, NEFFY, NEXLETOL, OTEZLA, Omnipod, Ozempic, PAXLOVID, PEDIARIX, PENMENVY, PREVNAR 20, Prolastin-C Liquid, REPATHA, ROTATEQ, Rybelsus, SHINGRIX, SKYRIZI, TONMYA, TRELEGY ELLIPTA, TREMFYA, The Cologuard Plus Collection Kit, VAXELIS, VAXNEUVANCE, VIVITROL, VOQUEZNA, VRAYLAR, VYNDAMAX, Veltassa, Veozah, Wegovy, ZENPEP, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error